FDAnews Drug Daily Bulletin

ACUITY PHARMACEUTICALS CONTINUES PIPELINE EXPANSION

April 21, 2006
A A

Acuity Pharmaceuticals, Inc., a clinical stage, product-focused ophthalmic pharmaceutical company, today announced that it has in-licensed exclusive worldwide development and commercialization rights to N-chlorotaurine (NCT), a novel, clinical stage, small molecule agent for the treatment of ophthalmic infections and other conditions. Acuity's lead compound, Cand5, is in clinical trials for wet age- related macular degeneration and diabetic macular edema, and represents the first clinical use of the gene-silencing technology called RNA interference. Yahoo News (http://biz.yahoo.com/prnews/060420/nyth086.html?.v=41)